Active Pharmaceutical Ingredients by Photochemical Deracemization: Chromanes as a Test Case

04 September 2025, Version 1
This content is an early or alternative research output and has not been peer-reviewed by Cambridge University Press at the time of posting.

Abstract

Chromanes are frequently encountered as chiral structure elements in active pharmaceutical ingredients (APIs). We have now discovered an access to enantiopure chromanes, which employs a 1:1 mixture of their enantiomers (racemate) in a photochemical deracemization reaction. A chiral photocatalyst acts by selective hydrogen abstraction at one chromane enantiomer and establishes a photostationary state in which the other enantiomer prevails. A thiol additive secures the stability of the photocatalyst and guarantees a high number of turnovers. The method was applied to the concise preparation of five chromane-containing drugs (Doxazosin, Fidarestat, Nebivolol, Repinotan, Sarizotan) as single enantiomers. Given the increasing need for enantiomerically pure compounds in medicinal chemistry, we anticipate that this study will have a broad impact in the field of enantioselective API synthesis.

Keywords

Deracemization
Hydrogen Atom Transfer
C-H Activation
Active Pharmaceutical Ingredients
Enantioselectivity
Chirality
Computation

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
Materials and Methods Supplementary Text Figs. S1 to S19 Tables S1 to S10
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting and Discussion Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.